Intelligent recommendation method for traditional Chinese medicine prescriptions

Abstract

The invention provides a traditional Chinese medicine prescription intelligent recommendation method, which comprises the following steps: analyzing decoction compatibility among medicines according to medicine classification to obtain a compatibility relationship among the medicines, and if the compatibility relationship shows an inhibition effect, adjusting classification priorities of hard medicines and aromatic medicines according to component release priorities to determine decoction groups; the medicinal material dissolution difficulty of the decoction groups is analyzed, the dissolution rule is obtained by recognizing the effective component content and the dissolution speed of each decoction group, and the hardness and volatility of the medicinal materials are evaluated to determine the heating intensity and the decoction time; and identifying the efficacy of the conflicting medicines, matching similar alternative medicines according to the efficacy of the conflicting medicines, and readjusting the feeding sequence of the medicinal materials and the fire switching opportunity according to the texture characteristics and chemical components of the alternative medicines to obtain a conflict-free link decoction process.

Description

TECHNICAL FIELD

[0001] The present application relates to the field of information technology, and in particular to a traditional Chinese medicine prescription intelligent recommendation method. BACKGROUND

[0002] Decoction as an important part of the prescription, different medicinal materials due to the differences in texture, chemical composition and pharmacodynamic release regularity, the demand for different decoction conditions are not the same. The traditional decoction method is often difficult to meet the modern medicine on the precision and individualization when facing complex prescription, which makes how to optimize the decoction process become an important topic of traditional Chinese medicine modernization. For example, hard mineral medicine needs long time high temperature decoction to release effective components, and volatile components in aromatic medicine are easy to lose if decocting too early. This "one size fits all" decoction method is difficult to take into account the characteristics of various medicinal materials, resulting in some of the pharmacodynamic can not be fully released, and even may be weakened due to improper decoction the overall efficacy. The deeper challenge is that the interaction between drugs in the prescription further complicates the decoction process. The texture characteristics of the drug determine the dissolution regularity of its effective components, and different medicinal materials may produce mutual inhibition or promotion due to the differences in chemical or physical properties during the decoction process. For example, some mineral medicines may react with volatile components of aromatic medicines during long time high temperature decoction, reducing the release efficiency of the latter. This drug interaction makes it difficult to simply rely on experience to adjust the decoction order or time to accurately meet the dissolution requirements of each drug. Further difficulty is how to determine the decoction method and condition according to the characteristics of each drug. Hard texture medicine needs to be decocted first to fully dissolve the effective components, while aromatic medicine needs to be added later to retain its volatile components. However, the existing method often lacks systematic analysis means, and cannot dynamically adjust the decoction time, fire strength and drug liquid concentration according to the specific properties of the drug. Therefore, how to arrange the decoction order, time and fire of different drugs according to the texture characteristics and interaction of different drugs in the prescription, while ensuring that the drug liquid concentration is moderate and easy to take, has become a technical problem to be solved. SUMMARY

[0003] The present application provides a traditional Chinese medicine prescription intelligent recommendation method, mainly comprising:

[0004] Extracting the texture characteristics and chemical composition of medicinal materials from the database, classifying the medicinal materials according to the texture characteristics and chemical composition, obtaining the classification results of hard and aromatic medicinal materials, and determining the decoction requirement category of each medicinal material according to the classification results;

[0005] According to the classification results, the decoction compatibility between the medicinal materials is analyzed, the compatibility relationship is constructed, the priority of the hard and aromatic medicinal materials is adjusted according to the inhibition effect in the compatibility relationship, and the decoction grouping is determined;

[0006] By analyzing the dissolution difficulty of each medicinal material in the decoction grouping, the content of effective components and the dissolution speed are determined, and the dissolution rule is obtained. According to the dissolution rule and the hardness and volatility of the medicinal materials, the fire strength and decoction time are determined;

[0007] The decoction is performed according to the fire strength and decoction time, the component concentration of medicinal liquid in the decoction process is detected, the fire strength is adjusted according to the component concentration and dissolution speed, and a concentration control scheme is generated;

[0008] The decoction conditions of each medicinal material are extracted from the concentration control scheme, and the overall decoction process including the medicinal material input sequence and the fire switching time are generated in combination with the decoction grouping. By analyzing the time node overlap, the conflict link is identified, and the conflict medicine existing in the overall decoction process is determined;

[0009] According to the efficacy of the conflict medicine, a substitute medicine is matched, and the overall decoction process is adjusted according to the texture characteristics and chemical components of the substitute medicine, and a decoction process without conflict link is generated;

[0010] By analyzing the influence of the substitute medicine on the component concentration of medicinal liquid in the decoction process without conflict link, the matching degree of the target component release path and the prescription requirement is verified, and a modified prescription containing substitute components and a differential decoction scheme are generated.

[0011] Further, the texture characteristics and chemical components of medicinal materials are extracted from the database, the medicinal materials are classified according to the texture characteristics and chemical components, the classification results of hard and aromatic medicinal materials are obtained, and the decoction requirement categories of each medicinal material are determined according to the classification results, including:

[0012] The physical hardness and volatile component data of medicinal materials are extracted from the database, and the medicinal materials are determined to be hard or aromatic according to the physical hardness and volatile component data;

[0013] The hard medicinal materials are configured with a first decoction mark and a fire parameter matched with the hard medicinal materials, and the aromatic medicinal materials are configured with a second decoction mark and a fire parameter matched with the aromatic medicinal materials. The decoction requirement categories of each medicinal material are generated according to the correspondence between the classification results and the fire parameters.

[0014] Further, the decoction compatibility between medicinal materials is analyzed according to the classification results, the compatibility relationship is constructed, the priority of the hard and aromatic medicinal materials is adjusted according to the inhibition effect in the compatibility relationship, and the decoction grouping is determined, including:

[0015] The chemical component categories and contents of each medicinal material are extracted according to the classification results, a drug component interaction matrix is generated, the matrix element value represents the component change rate during co-decoction, and the compatibility relationship is determined according to the component change rate during co-decoction;

[0016] The inhibitory effect is identified by detecting changes in the content of precipitates or components in the co-decoction. The decoction order of the hard and aromatic herbs is adjusted according to the inhibitory effect and the clinical importance of the herbs to generate decoction groups that do not interfere with each other.

[0017] Furthermore, the step of analyzing the dissolution difficulty of each medicinal material in the decoction group to determine the content of effective components and the dissolution rate, obtaining the dissolution pattern, and determining the heat intensity and decoction time based on the dissolution pattern and the hardness and volatility of the medicinal materials includes:

[0018] For the medicinal materials in the decoction group, the initial content and dissolution rate of the effective components of each medicinal material are determined, and dissolution kinetic curves are generated;

[0019] The half-dissolution time and dissolution rate constant are determined based on the dissolution kinetic curve. The dissolution difficulty is determined based on the half-dissolution time and dissolution rate constant. The corresponding heat intensity and decoction time are configured based on the dissolution difficulty and the hardness and volatility of the medicinal material.

[0020] Furthermore, the step of performing decoction according to the heat intensity and decoction time, detecting the component concentration of the decoction during the decoction process, adjusting the heat intensity according to the component concentration and dissolution rate, and generating a concentration control scheme includes:

[0021] The decoction is performed according to the specified heat intensity and decoction time, and the concentration of the target component in the decoction is measured in real time to calculate the concentration of the decoction.

[0022] Based on the comparison between the concentration of the medicinal solution and the preset threshold, and combined with the dissolution rate, the range of heat adjustment is determined, the heat intensity is adjusted and the decoction time is updated, and a concentration control scheme including the adjusted heat intensity and time period is generated.

[0023] Furthermore, the decoction conditions of each medicinal material are extracted from the concentration control scheme, and combined with the decoction grouping to generate an overall decoction process including the order of adding medicinal materials and the timing of heat switching, and conflicting links are identified by analyzing the overlap of time points, and conflicting drugs that conflict with the overall decoction process are determined, including:

[0024] The heating temperature and decoction time of each medicinal material are extracted from the concentration control scheme. The order of adding medicinal materials and the timing of switching the heat are arranged according to the decoction group to generate the overall decoction process.

[0025] By analyzing the timeline of the overall decoction process, the temperature difference during different decoction periods of medicinal materials is identified, time conflict points are marked, and conflicting drugs that conflict with the overall decoction process are determined based on the time conflict points.

[0026] Furthermore, the step of matching alternative drugs based on the efficacy of the conflicting drugs, and adjusting the overall decoction process based on the texture characteristics and chemical composition of the alternative drugs to generate a decoction process without conflicting elements, includes:

[0027] The efficacy category and indications of the conflicting drugs are queried, and candidate alternative drugs with similar efficacy are screened from the database;

[0028] The texture characteristics and chemical composition of candidate alternative drugs are detected, the parameter difference between the candidate alternative drugs and the conflicting drugs is calculated, the drug with the smallest difference is selected as the alternative drug, the addition time and heat intensity are reset according to the texture characteristics and chemical composition of the alternative drugs, the overall decoction process is updated, and a decoction process without conflicting links is generated.

[0029] Furthermore, by analyzing the impact of substitute drugs on the concentration of medicinal components in the conflict-free decoction process, the matching degree between the target component release pathway and the prescription requirements is verified, and a modified prescription and differentiated decoction scheme containing substitute components are generated, including:

[0030] The concentration of the medicinal liquid components after the execution of the conflict-free decoction process was measured, and the concentration change rate and the change in the proportion of effective components caused by the substitute drug were calculated.

[0031] Based on the changes in concentration and component ratio, the target component release deviation is calculated by comparing it with the prescription requirements. The decoction time and heat intensity are adjusted to generate a modified prescription and a differentiated decoction scheme that includes alternative drug names, grouped decoction sequences and concentration control standards.

[0032] The technical solutions provided by the embodiments of the present invention may include the following beneficial effects:

[0033] This invention discloses an intelligent prescription recommendation method for traditional Chinese medicine (TCM). Addressing the problems of incompatibility, low dissolution efficiency, and difficulty in controlling decoction concentration caused by differences in the texture and composition of medicinal materials in traditional TCM decoction, this method extracts the texture characteristics and chemical components of medicinal materials, classifying them into hard and aromatic categories. It analyzes decoction compatibility and dissolution patterns, dynamically adjusts the heat intensity and decoction time, and generates a conflict-free decoction process. This invention identifies conflicting drugs and matches them with alternative drugs, optimizes the order of adding medicinal materials and the timing of heat switching, ensuring that the decoction concentration matches the therapeutic requirements. Ultimately, it achieves precise control of decoction component concentration, improves the release efficiency of effective components, reduces decoction complexity, and significantly improves the stability and consistency of TCM decoction, providing an intelligent solution for the modernization of TCM. Attached Figure Description

[0034] Fig. 1 This is a flowchart of a method for intelligent recommendation of traditional Chinese medicine prescriptions according to the present invention.

[0035] Fig. 2 This is a schematic diagram of a traditional Chinese medicine prescription intelligent recommendation method according to the present invention. Detailed Implementation

[0036] To further understand the content of this invention, a detailed description of the invention is provided in conjunction with the accompanying drawings and embodiments. The specific embodiments described herein are for illustrative purposes only and are not intended to limit the invention. It should also be noted that, for ease of description, only the parts relevant to the invention are shown in the accompanying drawings.

[0037] like Figs. 1-2 This embodiment of a method for intelligent recommendation of traditional Chinese medicine prescriptions may specifically include:

[0038] Step S101: Extract the texture characteristics and chemical composition of each herb from the pre-stored medicinal material information in the database, classify the herbs according to their texture characteristics and chemical composition, and determine the decoction requirements for each herb based on the herb classification. Herb classification includes hard herbs and aromatic herbs.

[0039] The physical hardness and volatile oil content data of medicinal materials are extracted from the database. The crystallinity parameter of the medicinal materials is determined by X-ray diffraction. When the physical hardness exceeds a first preset threshold and the crystallinity is higher than a second preset threshold, the material is classified as hard. When the volatile oil content exceeds a third preset threshold, the material is classified as aromatic. For the hard medicinal materials, a pre-decoction marking and high-temperature decoction parameters are configured. For the aromatic medicinal materials, a post-decoction marking and low-temperature decoction parameters are configured. By matching the correspondence between the medicinal material classification and the decoction parameters, the decoction requirement category for each medicinal material is obtained.

[0040] Specifically, in one embodiment, when extracting the physical hardness value of medicinal materials from the database, the Vickers hardness test is used to measure the medicinal material sample. The medicinal material is ground into powder, pressed into tablets, and a diamond indenter is used to apply a fixed load. The hardness value is calculated by measuring the diagonal length of the indentation. The volatile oil content is extracted by steam distillation. The medicinal material powder is placed in a volatile oil measuring instrument, heated and distilled for 4 hours, and the volume of volatile oil is read and converted into a percentage content. When determining the crystallinity parameter by X-ray diffraction, the medicinal material powder sample is placed on the sample stage of the diffractometer, and Cu-Kα rays are used to scan in the range of 5-80 degrees. The crystallinity is calculated by the intensity and full width at half maximum (FWHM) of the diffraction peaks. When the diffraction pattern shows sharp peaks and high peak intensity, it indicates that the internal crystal structure of the medicinal material has a high degree of order, corresponding to a higher crystallinity value. The crystallinity of mineral medicinal materials such as gypsum and talc usually exceeds a second preset threshold, while the crystallinity of plant medicinal materials is relatively low.

[0041] Preferably, the decoction parameters are set differently according to the characteristics of the medicinal materials. For hard medicinal materials, the high-temperature decoction parameters include the initial heating temperature, the constant temperature holding time, and the frequency of heat adjustment. For aromatic medicinal materials, the low-temperature decoction parameters are determined based on the boiling point range of the volatile oils. The release rate of volatile components is controlled by stepwise heating, establishing a precise match between the type of medicinal material and the decoction process.

[0042] Step S102: Analyze the compatibility of decoction among drugs according to drug classification to obtain the compatibility relationship between drugs. If the compatibility relationship shows an inhibitory effect, adjust the classification priority of hard and aromatic drugs according to the release priority of components to determine the decoction group.

[0043] Based on the drug classification results, the chemical component categories and content data of each drug are extracted, and a drug component interaction matrix is ​​constructed. The matrix element values ​​represent the component change rate when two drugs are decocted together. When the change rate exceeds a preset threshold, it is marked as a compatibility relationship. Effect type identification is performed on the compatibility relationship. Inhibitory effects are determined by detecting whether precipitates are formed or component content decreases in the co-decocted liquid. Release priorities are determined based on drug clinical importance scores and component dissolution time windows. Drugs with higher priority maintain their original decoction order. The decoction order is adjusted based on the release priority and inhibitory effect. Aromatic drugs that are inhibited and have low priority are moved to the later group. Drugs that have inhibitory effects on hard drugs are placed in different decoction batches. K-means clustering algorithm is used to merge drugs with similar compatibility within groups, resulting in decoction groups that do not interfere with each other.

[0044] Specifically, in one implementation, the construction of the drug component interaction matrix is ​​based on experimental data and database information. The main component categories of each drug, including alkaloids, flavonoids, saponins, volatile oils, etc., and the percentage content of each component, are extracted from a traditional Chinese medicine chemical component database. The matrix is ​​an n×n square matrix, where n is the number of drugs, and the matrix element Mij represents the component change rate when drug i and drug j are decocted together. Change rate data are obtained through comparative experiments of decocting them separately and decocting them together. When the absolute value of the change rate exceeds 15%, a significant compatibility relationship is considered to exist.

[0045] Specifically, the inhibitory effect was identified using a multi-index comprehensive judgment method. After centrifugation, the co-decoction was observed for precipitate formation, which was then quantified by gravimetric analysis. Simultaneously, high-performance liquid chromatography (HPLC) was used to detect the content of the main components; if the content of a certain component decreased by more than 20%, it was considered an inhibitory effect. Precipitate formation is usually due to complexation reactions or acid-base neutralization reactions between drug components, leading to the formation of poorly soluble compounds.

[0046] It should be noted that the determination of release priority comprehensively considers both clinical importance and dissolution kinetic characteristics. The clinical importance score is assigned based on the drug's position in the prescription: principal drug 10 points, assistant drug 7 points, adjuvant drug 5 points, and guiding drug 3 points. The component dissolution time window refers to the time range within which the active ingredient reaches its peak concentration, determined through dissolution curves. The priority calculation formula is: Priority value = Clinical importance score × 0.6 + Dissolution rate coefficient × 0.4.

[0047] Preferably, the K-means clustering algorithm is applied to group drugs based on their compatibility characteristics. The compatibility characteristics of each drug are vectorized, including the strength of compatibility with other drugs, temperature requirements, dissolution rate, etc. The number of clusters k is set to 3-5, and the optimal number of clusters is determined using the elbow rule. During the algorithm iteration process, the cluster centers are continuously updated until convergence. Drugs within the same cluster have high compatibility and can be decocted simultaneously.

[0048] In one possible implementation, the arrangement of decoction batches follows the principle of minimizing conflict. Aromatic herbs that are inhibited and have low priority, such as peppermint and cardamom, are added last to reduce volatilization losses. Herbal medicines that have an inhibitory effect on mineral-based herbs are separated into different batches to avoid simultaneous decoction.

[0049] For example, when processing prescriptions containing gypsum, anemarrhena, and licorice, the interaction matrix showed that the glycyrrhizic acid content decreased by 25% when gypsum and licorice were decocted together, indicating an inhibitory effect. Licorice, being a low-priority adjuvant, was adjusted to be added 20 minutes after gypsum decoction, allowing for batch decoction and ensuring the full dissolution of the effective components of each drug.

[0050] Step S103: Analyze the dissolution difficulty of the medicinal materials in the decoction groups, identify the effective component content and dissolution rate of each decoction group to obtain the dissolution pattern, and assess the hardness and volatility of the medicinal materials to determine the heat intensity and decoction time.

[0051] Dissolution difficulty was assessed for medicinal materials within each decoction group. The initial content of active ingredients in each herb was determined using high-performance liquid chromatography (HPLC). A dynamic leaching device was used to measure the dissolution rate of components at gradient temperatures, recording the changes in component concentration in the dissolution solution per unit time to construct dissolution kinetic curves. The half-dissolution time (the time required for the component concentration to reach half its maximum value) was calculated based on these curves. The dissolution rate constant was determined by combining the curve slope changes. When the half-dissolution time exceeded a first threshold and the dissolution rate constant was lower than a second threshold, the herbs were classified as having high dissolution difficulty, thus revealing the dissolution patterns for each group of herbs. Based on the high-dissolution-difficulty herbs identified in the dissolution patterns, the hardness value was measured using a Vickers hardness tester. The content of volatile components and their evaporation initiation temperature were detected using headspace gas chromatography (HGC). The decoction characteristic category of the herb was determined based on the ratio of hardness value to volatile component content. For each category of decoction characteristics, corresponding decoction parameters are configured. For medicinal materials with hardness values ​​exceeding preset values ​​and low volatile component content, high heat intensity and long decoction time are set. For medicinal materials with high volatile component content and low evaporation initiation temperature, low heat intensity and short decoction time are set.

[0052] Specifically, in one embodiment, when assessing the dissolution difficulty of medicinal materials within a decoction group, high-performance liquid chromatography (HPLC) is used to determine the initial content of each active ingredient. The specific procedure includes pulverizing the medicinal material sample through a 40-mesh sieve, accurately weighing 1.0 g of powder, adding 50 mL of methanol, ultrasonically extracting for 30 minutes, centrifuging, and filtering the supernatant through a 0.45 μm microporous membrane. A C18 column is used with gradient elution of methanol-water as the mobile phase, and the detection wavelength is set to 254 nm. The initial content of each component is calculated using a standard curve.

[0053] Specifically, the application of the dynamic leaching device involves several key aspects. The main body of the device includes a constant-temperature water bath, a glass leaching column, a peristaltic pump, and an online detector. The medicinal sample is placed in the leaching column, and the solvent flows through the medicinal bed from the bottom at a constant flow rate. The concentration of components in the top effluent is monitored in real time by the online detector. Gradient temperature control starts at 60℃ and increases by 10℃ every 20 minutes until reaching 100℃. The concentration of the target component in the effluent per unit time is recorded under different temperature conditions, with data points collected every 5 minutes. By plotting time versus concentration curves, dissolution kinetic curves at each temperature are obtained. The dissolution kinetic curves exhibit a rapid initial rise, a gradual increase in the middle stage, and a plateau in the later stage, reflecting the dynamic process of the transfer of medicinal components from the cells to the solvent.

[0054] It should be noted that the calculation of the half-dissolution time is based on the mathematical processing of the dissolution kinetic curve. The maximum dissolution concentration Cmax is determined by curve fitting, and the half-dissolution time t1 / 2 is defined as the time required for the concentration to reach 0.5×Cmax. The dissolution rate constant k is obtained by fitting the first-order kinetic equation C=Cmax×(1-e^(-k×t)), where C is the concentration at time t. When the half-dissolution time exceeds 60 minutes and the dissolution rate constant is lower than 0.05min^-1, the medicinal material is judged to be in the category of high dissolution difficulty.

[0055] Preferably, the Vickers hardness test follows a standardized operating procedure. The thickness of the medicinal material slices is controlled at 2-3 mm, with a smooth surface free of cracks. A diamond indenter is vertically pressed into the sample surface with a load of 0.98 N, held for 15 seconds, and then unloaded. The diagonal lengths d1 and d2 of the indentation are measured, and the hardness value HV = 1.854 × F / (d1 × d2), where F is the load force. Five points are measured for each sample, and the average value is taken as the hardness value of the medicinal material.

[0056] In one possible implementation, when detecting volatile components using headspace gas chromatography, 2.0 g of the herbal powder is placed in a 20 mL headspace vial, 5 mL of distilled water is added, and the vial is sealed and equilibrated at 80 °C for 30 minutes. 1 mL of headspace gas is injected into the gas chromatograph using an autosampler, employing an HP-5 capillary column with nitrogen as the carrier gas at a flow rate of 1.0 mL / min. The temperature program is initiated at 40 °C for 2 minutes, then increased to 200 °C at a rate of 5 °C / min, with the FID detector temperature set to 250 °C. Qualitative analysis is performed using retention time, and the relative content of each volatile component is calculated using peak area normalization.

[0057] For example, the determination of decoction characteristic category involves a comprehensive evaluation of multi-dimensional parameters. The ratio of hardness value to volatile component content, R = HV / V%, is used as the main criterion, where HV is the Vickers hardness value and V% is the percentage content of volatile components. When R > 100, it is classified as hard and insoluble, with a decoction temperature of 95-100℃ and a decoction time of 45-60 minutes; when R is between 10 and 100, it is classified as moderately soluble, with a decoction temperature of 85-95℃ and a time of 30-45 minutes; when R < 10, it is classified as easily soluble and volatile, with a decoction temperature of 70-85℃ and a time of 15-30 minutes. Furthermore, the control of heat intensity adopts segmented temperature management. For hard and insoluble medicinal materials, the initial stage uses high heat to quickly raise the temperature to the set temperature, then switches to medium heat to maintain a constant temperature, and finally switches to low heat for the last 5 minutes to reduce the liquid. For easily soluble and volatile medicinal materials, a low flame is used to slowly raise the temperature to prevent the volatile components from escaping too quickly, and the temperature is maintained at a gentle boil after reaching the set value.

[0058] Understandably, the evaporation initiation temperature is determined using a thermogravimetric analyzer. A 10mg sample of the medicinal material is placed in a platinum crucible and heated from room temperature to 300℃ at a rate of 10℃ / min under nitrogen protection, and the mass loss curve is recorded. The temperature point at which the mass loss rate suddenly increases is the evaporation initiation temperature of the volatile components, and this parameter directly affects the setting of the upper limit of the decoction temperature.

[0059] For example, when processing groups containing aromatic medicinal materials such as peppermint and cardamom, the evaporation initiation temperature of menthol was detected to be 42℃, the volatile oil content reached 3.5%, and the hardness value was only 15HV, with a calculated R value of 4.3, classifying it as easily soluble and volatile. Accordingly, the decoction parameters were configured as follows: temperature 75℃, time 20 minutes, and a closed decoction device was used to reduce volatilization loss. This combination of parameters ensured the full dissolution of the active ingredients while avoiding excessive loss of volatile components.

[0060] Step S104: Decoction is carried out according to the heat intensity and decoction time. The concentration of the decoction is calculated by measuring the concentration of the components during the decoction process. If the concentration of the decoction exceeds the preset concentration threshold, the heat intensity is reduced according to the dissolution rate to obtain the concentration control scheme.

[0061] The decoction process is performed based on the heat intensity and decoction time. An online ultraviolet spectrophotometer is used to measure the absorbance of the target component in the decoction at preset time intervals. The real-time component concentration is calculated using a standard curve, and the cumulative concentration at each time point is divided by the liquid volume to obtain the drug concentration. The drug concentration is compared with a preset concentration threshold. If the threshold is exceeded, the dissolution rate data at the current moment is extracted. The dissolution rate is obtained by dividing the concentration difference between two adjacent measurement points by the time interval. The heat adjustment range is determined based on the ratio of the dissolution rate to the standard dissolution rate. Based on the heat adjustment range, the current heat intensity is reduced. The reduced heat intensity is equal to the original heat intensity multiplied by the reciprocal of the adjustment range. Simultaneously, the required extended decoction time is calculated based on the relationship between the temperature reduction and the dissolution rate. The heat adjustment values ​​for each time period are recorded. The heat adjustment values ​​and corresponding time period data are integrated to form a concentration control scheme, which includes the initial heat intensity, the adjusted heat intensity for each time period, the start and end times of each stage, and the total decoction time.

[0062] Specifically, in one embodiment, during the decoction operation according to preset heat intensity and decoction time, an online ultraviolet spectrophotometer is used for real-time monitoring. The device's light source emits ultraviolet light of a specific wavelength that passes through the decoction liquid flow cell, and the detector receives the transmitted light intensity, calculating the absorbance value according to Lambert-Beer's law. The flow cell is connected to the decoction container via a circulation pipeline, and a peristaltic pump draws the decoction liquid at a constant flow rate, passes it through the detection cell, and then returns it to the decoction container, achieving non-destructive continuous monitoring.

[0063] Specifically, the conversion of component concentrations involves the establishment and application of standard curves. A series of standard solutions with varying concentration gradients are prepared in advance, and the absorbance values ​​corresponding to each concentration are measured. A standard curve of absorbance versus concentration is established through linear regression. During the actual decoction process, absorbance data is automatically recorded every 5 minutes, and the component concentration at that moment is calculated by substituting it into the standard curve equation. The cumulative concentration is calculated using an integral method, summing the instantaneous concentration values ​​at each time point multiplied by the time interval, and then dividing by the actual volume of the decoction to obtain the average concentration value of the decoction. This cumulative calculation method considers the volume change caused by water evaporation during the decoction process. The liquid level is monitored in real time by a liquid level sensor, and the current liquid volume is calculated based on the container's cross-sectional area, ensuring the accuracy of the concentration calculation.

[0064] It should be noted that the preset concentration thresholds are determined based on pharmacopoeia regulations and clinical medication needs. Different types of traditional Chinese medicine prescriptions have corresponding concentration standard ranges. Excessively high concentrations can lead to overly viscous and difficult-to-take decoctions, and excessively high concentrations of certain components may cause adverse reactions. The threshold settings take into account the limits of toxic components in the medicinal materials, the therapeutic concentration range of the effective components, and patient tolerance.

[0065] Preferably, the dissolution rate is calculated using the differential method to process continuous monitoring data. The concentration values ​​at two adjacent measurement times t1 and t2 are C1 and C2, respectively, and the dissolution rate v = (C2 - C1) / (t2 - t1). The standard dissolution rate is preset according to the type of medicinal material, and the range of dissolution rates for various medicinal materials under normal decoction conditions is obtained through statistical analysis of a large amount of experimental data.

[0066] In one possible implementation, the determination of the heat intensity adjustment range is based on the principle of proportional control. When the ratio k = v / v0 of the measured dissolution rate v to the standard dissolution rate v0 is greater than 1, it indicates that the dissolution is too fast and the heat intensity needs to be reduced. The formula for calculating the adjustment range is: adjusted heat intensity = original heat intensity / k. This inverse proportional adjustment ensures that the dissolution rate returns to the standard range.

[0067] For example, the relationship between the temperature reduction and the extended cooking time is derived using the Arrhenius equation. For every 10°C decrease in temperature, the chemical reaction rate decreases by approximately 2-3 times, correspondingly requiring a 2-3 times longer cooking time to achieve the same dissolution effect. Specifically, the extended cooking time Textended = Toriginal × 2^(ΔT / 10), where Toriginal is the original cooking time and ΔT is the temperature reduction. Furthermore, the record of the heat adjustment values ​​includes a timestamp, the heat before adjustment, the heat after adjustment, and the reason for the adjustment. Each adjustment operation is recorded in the database, forming a complete adjustment history.

[0068] Understandably, the formation of a concentration control scheme is a dynamic optimization process. The scheme includes multiple control parameters. The initial heat intensity is usually set at 80% of the rated power to leave room for subsequent adjustments. Each time period is divided according to the dissolution characteristics of the medicinal materials, such as 0-10 minutes for the rapid dissolution period, 10-30 minutes for the stable dissolution period, and after 30 minutes for the slow dissolution period. Each time period corresponds to a different heat intensity setting value. The start and end times are accurate to the second to ensure control precision. The total decoction time is determined based on the time required for all medicinal materials to fully dissolve.

[0069] For example, when processing prescriptions containing tonifying herbs such as Astragalus and Angelica sinensis, the initial heat intensity was set to 1500W. After 10 minutes of decoction, the concentration of the decoction reached 12g / 100mL, exceeding the preset threshold of 10g / 100mL. At this point, the dissolution rate was 0.8g / (100mL·min), which is 1.6 times the standard rate of 0.5g / (100mL·min). The heat intensity was adjusted to 1500W / 1.6 = 937.5W, and the decoction time was extended by 8 minutes, based on a temperature reduction of approximately 15℃. Through this dynamic adjustment, the final concentration of the decoction stabilized within the suitable range of 9.5g / 100mL.

[0070] Step S105: Extract the specific decoction conditions of each herb in the decoction group from the concentration control scheme, generate the overall decoction process by combining the decoction groups, identify conflicting links by checking the overlap of time nodes, evaluate the compatibility of the decoction conditions of each herb with the overall process, and identify conflicting herbs with significant differences in decoction complexity and serious conflicts with the overall process.

[0071] The decoction parameters for each herb are analyzed from the concentration control scheme. The corresponding heating temperature and decoction time for each herb are read, and the staged temperature setpoints and durations are obtained based on the dissolution characteristics of the herbs at different stages. Based on these decoction parameters and decoction groupings, the order of herb addition is arranged. For hard herbs, the addition time is set to zero; for aromatic herbs, the next addition time is determined based on their volatilization temperature. The required heat adjustment operations at each time point are recorded, forming an overall decoction process that includes the addition order and heat switching timing. A timeline analysis is performed on the overall decoction process to identify overlapping intervals in the decoction periods of different herbs. When the temperature difference required by two or more herbs in the same time period exceeds a preset threshold, it is marked as a time conflict point, and the number of conflict points is counted. The compatibility of each herb with the overall process is evaluated based on these time conflict points. If the temperature requirement of a certain herb differs from that of other herbs by more than a first threshold and the number of conflict points exceeds a second threshold, the herb is determined to be in serious conflict with the overall process and is identified as a conflicting herb.

[0072] Specifically, in one implementation, the process of parsing decoction parameters from the concentration control scheme involves multi-level data extraction. The concentration control scheme is stored in the form of a structured data table, which contains fields such as drug name, belonging group, temperature sequence, and duration sequence. The records of each drug are read through the data parsing interface, and the heating temperature numerical sequence such as 60°C - 80°C - 95°C and the corresponding duration sequence such as 10 minutes - 20 minutes - 15 minutes are extracted. According to the dissolution kinetics characteristics of the drug during decoction, the temperature sequence is mapped to stage control parameters, and different temperature setting values correspond to the initial rapid heating stage, the middle constant temperature maintenance stage, and the final slow cooling stage respectively.

[0073] Specifically, the arrangement of the order of putting in the medicinal materials follows the method of combining traditional decoction theory and modern pharmacology principles. For hard medicinal materials such as gypsum and dragon bones (mineral drugs), the cell walls are dense and the effective components are slowly dissolved, and a long-time high-temperature decoction is required to fully release the medicinal effect components. Therefore, the putting-in time is set to the zero moment, that is, they are put in at the beginning of decoction. Aromatic medicinal materials such as mint and agastache contain a large amount of volatile components, and the boiling points of these components are generally between 40 - 80°C. Putting them in too early will cause a large loss of volatile oil components. The main volatile components and their boiling points of each aromatic medicinal material are determined by gas chromatography - mass spectrometry, and the later-putting time of the medicinal material is determined according to the component with the lowest boiling point. When the total decoction time is 45 minutes, the medicinal materials with volatile component boiling points below 60°C are put in at the 35th minute, and the medicinal materials with boiling points between 60 - 80°C are put in at the 30th minute, forming a stepped medicine-putting time sequence. The record of the timing of fire adjustment includes the switching moment, the target fire value, and the reason for switching. Each moment point corresponds to a fire adjustment instruction, and a complete fire control sequence is formed through timestamp association.

[0074] It should be noted that the formation of the overall decoction process is the result of comprehensive optimization of multiple factors. The process data structure includes four core elements: time axis, medicinal material queue, temperature curve, and operation instructions. The time axis starts from the zero moment and records each key time node in seconds; the medicinal material queue is sorted by the putting-in time, and each element contains the medicinal material identifier, putting-in time, and required temperature; the temperature curve describes the temperature change trajectory of the entire decoction process; the operation instructions trigger corresponding control actions at specific moments.

[0075] Preferably, the time axis analysis uses an interval overlap detection algorithm. The decoction period of each drug is represented as a time interval [start moment, end moment], and by traversing all pairs of drugs, it is detected whether there is an intersection in their time intervals. When the interval [t1, t2] of drug A and the interval [t3, t4] of drug B satisfy max(t1, t3) < min(t2, t4), it is determined that there is a time overlap. For the overlapping period, the temperature values TA and TB required by the two drugs are extracted respectively, and the temperature difference |TA - TB| is calculated.

[0076] In one possible implementation, the identification of time conflict points is based on a temperature difference threshold. A preset temperature difference threshold of 15°C is used; when the temperature difference between two or more drugs within an overlapping time period exceeds this threshold, that time period is marked as a conflict period. The number of conflict points throughout the entire decoction process is counted, and each conflict period is assigned a different weight based on its duration and the number of drugs involved.

[0077] For example, the compatibility assessment employs a multi-dimensional comprehensive scoring mechanism. The assessment dimensions include three aspects: the degree of temperature difference, the proportion of conflicting periods, and the importance level of the drug. The degree of temperature difference is obtained by calculating the average temperature difference between the drug and all other drugs; the proportion of conflicting periods is the total duration of all conflicting periods involving the drug divided by its total decoction time; the importance level of the drug is determined according to the principal, assistant, adjuvant, and guide roles in the prescription, with the principal drug given a higher weight. Furthermore, the determination of conflicting drugs involves a dual-threshold judgment mechanism. The first threshold concerns temperature difference; when the average temperature difference between a drug and other drugs exceeds 20°C, the first judgment condition is triggered. The second threshold concerns conflict frequency; when the number of conflict points exceeds 5, the second judgment condition is triggered. Drugs that simultaneously meet both conditions are judged as conflicting drugs that seriously conflict with the overall process.

[0078] Understandably, this conflict identification mechanism can accurately pinpoint key points of conflict in the decoction process. By quantitatively analyzing the compatibility indicators of various drugs, it provides data support for subsequent process optimization and drug substitution, enabling refined management of the decoction process.

[0079] For example, when processing a compound formula containing gypsum, coptis chinensis, and peppermint, gypsum needs to be decocted at 95℃ for 45 minutes, coptis chinensis at 85℃ for 30 minutes, and peppermint at 70℃ for 10 minutes. Timeline analysis shows that during the 30-40 minute timeframe, all three herbs were being decocted simultaneously, but at temperatures of 95℃, 85℃, and 70℃ respectively, with a maximum temperature difference of 25℃, exceeding the preset threshold. Peppermint was identified as a conflicting herb due to its significantly different temperature requirements compared to the other herbs and its conflict with the herb at five different time points.

[0080] Step S106: Identify the efficacy of conflicting drugs, match similar alternative drugs based on the efficacy of conflicting drugs, and readjust the order of adding medicinal materials and the timing of switching the heat according to the texture characteristics and chemical composition of the alternative drugs to obtain a decoction process without conflicting steps.

[0081] The efficacy categories and indications of conflicting drugs are queried. Data on the properties, functions, indications, and pharmacological effects of these drugs are extracted from a drug efficacy database. A text similarity matching algorithm is used to calculate the efficacy similarity between other drugs and the conflicting drugs. Drugs with similarity exceeding a preset threshold are selected as candidate alternatives. Texture characteristics and chemical composition are analyzed for these candidate alternatives to obtain their hardness value, volatile oil content, and main active ingredient content. The sum of the differences between these parameters and the corresponding parameters of the original conflicting drug is calculated, and the drug with the smallest sum of differences is selected as the alternative. A new addition time is determined based on the hardness value of the alternative drug. The heat intensity values ​​for each time period are reset according to the dissolution rate of the alternative drug, based on the volatile oil content and the next time point. The drug addition records and heat settings at each time point in the decoction process are updated to obtain a decoction process without conflicting steps.

[0082] Specifically, in one implementation, when querying the efficacy of conflicting drugs, multi-dimensional information is extracted from a drug efficacy database. The properties and meridian tropism include the drug's four natures and five flavors, and its meridian tropism, such as its classification as cold, hot, warm, cool, or neutral, and its meridian affiliation to the liver, heart, spleen, lung, and kidney. The functions and indications cover the drug's main therapeutic effects, such as clearing heat and detoxifying, promoting blood circulation and removing blood stasis, and tonifying qi and nourishing blood. The pharmacological effects record the biological activities confirmed by modern pharmacological research, including mechanisms of action such as anti-inflammatory, antibacterial, and immunomodulatory effects.

[0083] Specifically, the text similarity matching algorithm uses the cosine similarity calculation method. The efficacy description text of each drug is segmented into words to construct word frequency vectors, and the cosine value of the angle between the vectors of conflicting drugs and candidate drugs is calculated. The similarity value ranges from 0 to 1; when the similarity exceeds 0.75, the two drugs are considered to have similar efficacy.

[0084] It should be noted that the detection of texture characteristics and chemical composition covers multiple parameter dimensions. Hardness values ​​are measured using a Vickers hardness tester, reflecting the density of the medicinal material's physical structure; volatile oil content is calculated as a percentage after extraction using steam distillation; and the content of major active ingredients is quantitatively analyzed using high-performance liquid chromatography. The calculation of the sum of differences employs normalization, converting each parameter to a standard value within the range of 0-1, and then calculating the sum of the absolute values ​​of the differences between the corresponding parameters of the substitute drug and the original drug.

[0085] Preferably, the process of adjusting the decoction procedure according to the characteristics of the alternative drugs is divided into three steps. The hardness value determines the addition time; for every 10 HV increase in hardness, the addition time is advanced by 5 minutes. The volatile oil content determines the subsequent addition time; for every 1% increase in content, the subsequent addition time is delayed by 3 minutes. The dissolution rate affects the heat intensity; for drugs with a fast dissolution rate, the heat intensity is reduced by 10-15%.

[0086] In one possible implementation, updating the decoction process involves adjusting global parameters. This involves recalculating the drug combinations at each time point, confirming the temperature requirements for decoction within the same time period, and adjusting the heat settings to meet the minimum temperature requirements of all drugs. Through this substitution and adjustment mechanism, existing temperature conflicts are eliminated, achieving stable operation of the decoction process.

[0087] For example, when the conflicting drug is ephedra, whose effects are to induce sweating, relieve exterior syndromes, and promote lung function and relieve asthma, perilla leaf, with similar effects, was found as a substitute through similarity matching. Perilla leaf has a low hardness value and a moderate volatile oil content. By adjusting the time of addition to perilla leaf to 20 minutes after the start of decoction and setting the heat to medium, temperature conflicts with other drugs were successfully avoided.

[0088] Step S107: Evaluate the specific changes in the concentration and proportion of active ingredients of the liquid by the substitute drug in the conflict-free decoction process. At the same time, verify the matching degree between the release path of the target ingredient and the efficacy requirements of the prescription by comparing the component content. Generate a modified prescription containing the suggestion of substitute ingredients and the corresponding differentiated decoction plan.

[0089] Liquid chromatography was used to determine the concentration of medicinal components in the decoction after the execution of the conflict-free decoction process. The concentration values ​​of each component in the original decoction were compared, and the concentration change rate caused by the substitute drug was calculated. The change in the proportion of effective components was determined by the peak area ratio. Based on the component proportion change data, the release time curve and cumulative release amount of the target component were extracted. By comparing the efficacy positioning and clinical dosage standards of each drug in the prescription, the percentage deviation between the actual release amount and the standard release amount of the target component was calculated, resulting in a matching score. Based on the matching score, drug groups requiring adjustment were selected. When the score was below a preset threshold, the decoction time and heat intensity of the drug group were increased. The dosing time, decoction temperature, and duration of each group after adjustment were recorded, forming a new grouped decoction sequence. Integrating the grouped decoction sequences and component concentration data, a modified prescription document was compiled, including the original drug name, the name of the substitute drug, the reason for substitution, the new decoction parameters, and the concentration control standards, resulting in a differentiated decoction scheme.

[0090] Specifically, in one embodiment, the process of determining the concentration of components in a medicinal solution using liquid chromatography involves two steps: sample pretreatment and instrumental analysis. After decoction, the medicinal solution is filtered through a 0.45 μm microporous membrane. 1 mL of the filtrate is diluted to 10 mL with the mobile phase, shaken well, and then 20 μL is injected. The chromatographic conditions are set as follows: C18 column, column temperature 30 °C, mobile phase gradient elution of methanol-0.1% phosphoric acid aqueous solution, flow rate 1.0 mL / min, and detection wavelength set according to the characteristic absorption peaks of different components. Qualitative analysis is performed by comparing the retention time with that of a standard, and quantification is performed using the external standard method based on peak area. The medicinal solutions from both the original and conflict-free procedures are measured separately, with each sample measured in triplicate and the average value taken.

[0091] Specifically, the calculation of the concentration change rate involves a comprehensive evaluation of multiple components. For each detected component peak, its peak area A and corresponding concentration C are recorded. The formula for calculating the concentration change rate caused by the substitute drug is: Change Rate = (Csubstitute - Coriginal) / Coriginal × 100%. A positive change rate indicates an increase in the concentration of the component; a negative value indicates a decrease in concentration. The proportion of the effective component is determined by the percentage of each component peak area to the total peak area. Changes in the proportions of the principal, assistant, and adjuvant components directly reflect the degree of change in the overall efficacy of the prescription. By comparing the component fingerprint spectra before and after substitution, newly added and disappeared component peaks are identified, and the impact of the substitute drug on the overall component composition is assessed. This quantitative analysis provides objective data support for subsequent efficacy evaluation.

[0092] It should be noted that the release curve of the target component was constructed based on time-series sampling. Samples were taken every 5 minutes during the decoction process, and monitoring was conducted continuously for 45 minutes to obtain concentration data at 10 time points. A release kinetic curve was plotted with time on the x-axis and component concentration on the y-axis. The cumulative release amount was obtained by integrating the area under the curve.

[0093] Preferably, the determination of the standard release amount is based on pharmacopoeia regulations and clinical research data. The lower limit values ​​for the content determination of each medicinal material are obtained from the Chinese Pharmacopoeia, and the theoretical release amount is calculated in conjunction with the clinically effective dose range. The deviation percentage is calculated as follows: (Actual release amount - Standard release amount) / Standard release amount × 100%. When the deviation is within ±20%, the matching score is 80-100 points; when the deviation is ±20-40%, the score is 60-80 points; and when the deviation exceeds ±40%, the score is below 60 points.

[0094] In one possible implementation, the adjustment strategy based on matching scores employs a tiered response mechanism. Drug groups with scores below 60 are prioritized for adjustment, requiring simultaneous increases in decoction time and heat intensity. The extent of the decoction time extension is determined based on the texture of the medicinal materials: 15-20 minutes for hard materials and 10-15 minutes for medium-hard materials. Heat intensity adjustment uses a step-by-step approach, initially increasing by 20%, and if still insufficient, increasing by another 10%, but not exceeding 150% of the original heat intensity.

[0095] For example, the formation process of the grouped decoction sequence includes timing planning and parameter configuration. All medicinal materials are sorted from morning to night according to the adjusted addition times, forming a dosing schedule. Each time point is labeled with the name, weight, and corresponding heat setting of the medicinal material to be added. The decoction temperature is determined based on the highest temperature requirement of the currently decocted medicinal materials, ensuring that the minimum temperature requirement of all decocted medicinal materials is met. The duration is calculated from the addition of the last medicinal material in the group until the minimum required decoction time for that group of medicinal materials. Furthermore, the preparation of the modified prescription document follows a standardized format. The document includes four parts: basic prescription information, a substitute drug comparison table, a decoction parameter adjustment table, and concentration control indicators. The substitute drug comparison table lists the original drug name, the substitute drug name, the reason for substitution (e.g., "temperature requirement conflict"), and the efficacy similarity score. The decoction parameter adjustment table records in detail the addition time, decoction temperature, duration, and heat intensity of each medicinal material. The concentration control indicators set the target concentration range and allowable deviation for each major component.

[0096] Understandably, the implementation of differentiated decoction schemes requires precise process control. The scheme clearly specifies the requirements for decoction equipment, such as electromagnetic decoction machines with programmed temperature control; the operating procedures are detailed down to the specific actions at each time point; and quality control points are set at key stages, including verification of medicinal materials before administration, temperature monitoring during decoction, and concentration testing after decoction.

[0097] For example, a certain heat-clearing and detoxifying formula contains honeysuckle, forsythia, and scutellaria. The original formula had a temperature conflict between adding honeysuckle later and decocting scutellaria first. Through efficacy matching, honeysuckle vine was found to replace honeysuckle, as it has a lower volatile oil content and can be decocted together with scutellaria. The adjusted formula changed the method to decocting honeysuckle vine first, with a uniform decoction temperature of 90℃, avoiding temperature switching. The contents of chlorogenic acid and baicalin in the decoction reached 2.5 mg / mL and 3.2 mg / mL respectively, meeting the therapeutic requirements. Through this systematic evaluation and adjustment, the decoction process was optimized.

[0098] It should also be noted that the various specific technical features described in the above embodiments can be combined in any suitable manner without contradiction. To avoid unnecessary repetition, the present invention will not describe the various possible combinations separately. Furthermore, various different embodiments of the present invention can also be arbitrarily combined, as long as they do not violate the spirit of the present invention, and should also be regarded as the content disclosed by the present invention.

Claims

1. A method for intelligent recommendation of a traditional Chinese medicine prescription, characterized in that, The method comprises the following steps: extracting the texture features and chemical components of medicinal materials from a database, classifying the medicinal materials according to the texture features and chemical components, obtaining the classification results of hard and aromatic medicinal materials, and determining the decoction requirement categories of each medicinal material according to the classification results; analyzing the decoction compatibility among medicinal materials according to the classification results, constructing a compatibility relationship, adjusting the priority of the hard and aromatic medicinal materials according to the inhibition effect in the compatibility relationship, and determining the decoction grouping; determining the effective component content and dissolution rate by analyzing the dissolution difficulty of each medicinal material in the decoction grouping, obtaining the dissolution rule, and determining the fire intensity and decoction time according to the dissolution rule and the hardness and volatility of the medicinal materials; performing decoction according to the fire intensity and decoction time, detecting the component concentration of medicinal liquid in the decoction process, adjusting the fire intensity according to the component concentration and dissolution rate, and generating a concentration control scheme; extracting the decoction conditions of each medicinal material from the concentration control scheme, combining the decoction grouping to generate an overall decoction process including the medicinal material input sequence and fire switching time, identifying the conflict links by analyzing the time node overlap, and determining the conflict drugs that exist conflicts with the overall decoction process; matching a substitute drug according to the efficacy of the conflict drug, adjusting the overall decoction process according to the texture features and chemical components of the substitute drug, and generating a decoction process without conflict links; verifying the matching degree of the target component release path and the prescription requirement by analyzing the influence of the substitute drug on the component concentration of medicinal liquid in the decoction process without conflict links, and generating a modified prescription containing a substitute component and a differential decoction scheme. 2.The method of claim 1, wherein, The method comprises the following steps: extracting the texture features and chemical components of medicinal materials from a database, classifying the medicinal materials according to the texture features and chemical components, obtaining the classification results of hard and aromatic medicinal materials, and determining the decoction requirement categories of each medicinal material according to the classification results; extracting the physical hardness and volatile component data of medicinal materials from a database, determining whether the medicinal materials are hard or aromatic according to the physical hardness and volatile component data; 3.The method of claim 1, wherein, configuring a first decoction mark and a fire parameter matched with the hard medicinal materials for the hard medicinal materials, configuring a second decoction mark and a fire parameter matched with the aromatic medicinal materials for the aromatic medicinal materials, and generating the decoction requirement categories of each medicinal material according to the correspondence between the classification results and the fire parameters. The method comprises the following steps: extracting the chemical component categories and contents of each medicinal material according to the classification results, generating a drug component interaction matrix, and determining the compatibility relationship according to the component change rate during decoction; identifying the inhibition effect by detecting the precipitate or component content change in the decoction liquid, adjusting the decoction sequence of the hard and aromatic medicinal materials according to the inhibition effect and the clinical importance of the medicinal materials, and generating a decoction grouping without mutual interference.

4. The Chinese medicine prescription intelligent recommendation method according to claim 1, characterized in that, The effective component content and dissolution rate are determined by analyzing the dissolution difficulty of each medicinal material in the decoction grouping, the dissolution rule is obtained, the fire strength and decoction time are determined according to the dissolution rule and the hardness and volatility of the medicinal material, and the method comprises: The initial content and dissolution rate of the effective component of each medicinal material in the decoction grouping are determined, and a dissolution kinetics curve is generated; The half-dissolution time and dissolution rate constant are determined according to the dissolution kinetics curve, the dissolution difficulty is determined according to the half-dissolution time and dissolution rate constant, and the corresponding fire strength and decoction time are configured according to the dissolution difficulty and the hardness and volatility of the medicinal material.

5. The method of claim 1, wherein the method further comprises: The decoction is performed according to the fire strength and decoction time, the concentration of the medicinal liquid in the decoction process is detected, the fire strength is adjusted according to the concentration and dissolution rate, and a concentration control scheme is generated, which comprises: The decoction is performed according to the fire strength and decoction time, the concentration of the target component in the decoction liquid is determined in real time, and the medicinal liquid concentration is calculated; According to the comparison result of the medicinal liquid concentration and the preset threshold value, the fire adjustment range is determined in combination with the dissolution rate, the fire strength is adjusted, the decoction time is updated, and a concentration control scheme containing the adjusted fire strength and time period is generated. 6.The method of claim 1, wherein, The decoction conditions of each medicinal material are extracted from the concentration control scheme, the overall decoction process containing the medicinal material input sequence and the fire switching time is generated in combination with the decoction grouping, the conflict links are identified by analyzing the time node overlap, and the conflict drugs existing in the overall decoction process are determined, which comprises: The heating temperature and decoction time of each medicinal material are extracted from the concentration control scheme, the medicinal material input sequence and the fire switching time are arranged according to the decoction grouping, and the overall decoction process is generated; By analyzing the time axis of the overall decoction process, the temperature difference of different medicinal material decoction period is identified, the time conflict point is marked, and the conflict drugs existing in the overall decoction process are determined according to the time conflict point.

7. The Chinese medicine prescription intelligent recommendation method according to claim 1, characterized in that, The substitute drug is matched according to the efficacy of the conflict drug, the overall decoction process is adjusted according to the texture characteristics and chemical components of the substitute drug, and a conflict-free decoction process is generated, which comprises: The efficacy category and the main indication of the conflict drug are queried, and the candidate substitute drugs with similar efficacy are screened from the database; The texture characteristics and chemical components of the candidate substitute drug are detected, the parameter difference between the candidate substitute drug and the conflict drug is calculated, the drug with the smallest difference value is selected as the substitute drug, the input time and the fire strength are reset according to the texture characteristics and chemical components of the substitute drug, the overall decoction process is updated, and a conflict-free decoction process is generated. 8.The method of claim 1, wherein, The influence of the substitute drug in the conflict-free decoction process on the concentration of the medicinal liquid component is analyzed, the matching degree of the target component release path and the prescription demand is verified, a modified prescription containing the substitute component and a differential decoction scheme are generated, which comprises: The concentration of the medicinal liquid component after the execution of the conflict-free decoction process is determined, the concentration change rate caused by the substitute drug and the effective component proportion change are calculated; According to the concentration change rate and the component proportion change, comparing with the prescription demand, calculating the target component release amount deviation, adjusting the decoction time and the fire strength, generating the modified prescription and the differentiated decoction scheme containing the alternative drug name, the grouped decoction sequence and the concentration control standard.

Images